NCT01437943

Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients

P-MR Spectroscopy Evaluation of the Effect of Short-Term Treatment With Aliskiren on Kidney β-ATP/Pi Level in Kidney Transplant Patients

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effect of a short-term aliskiren treatment on kidney metabolism in patients at high risk for developing kidney dysfunction (i.e. kidney transplanted patients). The study is aimed at evaluating if any effect on kidney metabolism \[using proton MR Spectroscopy(1H-MRS)\] can be detected following a 6 months treatment with aliskiren regardless of its anti-hypertensive role. 1H-MRS can record a larger number of chemical species (up to 40) in the kidney, and monitor changes according to the pathologic state and health of the transplanted kidney.

Conditions

• Kidney Disease
• Kidney Failure, Chronic

Interventions

Type	Name	Description
DRUG	Aliskiren	Take 1 tablet (150 mg) by mouth daily for 180 days
DRUG	Placebo	Take 1 tablet (0 mg) daily for 180 days.

Timeline

• Start date: 2010-04-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2011-09-21
• Last updated: 2017-05-01
• Results posted: 2017-05-01

Locations

1 site across 1 country: United States